Find recruiting clinical trials for chronic lymphocytic leukaemia (CLL) in the UK — including next-generation BTK inhibitors, venetoclax-based combination strategies, CAR-T cell therapy for relapsed disease, and early intervention studies. See your treatment pathway and where trials fit in.
Free to use — Live data from ClinicalTrials.gov — Updated hourly
Answer a few questions about your condition and we'll match you to the most relevant clinical trials.
See where clinical trials fit into your treatment journey
Early CLL with no symptoms — monitoring only
Standard: Regular blood counts, clinical monitoring, no active treatment. Trials testing early intervention in high-risk genetics (TP53, unmutated IGHV)
Symptomatic or progressive CLL requiring therapy
Standard: Ibrutinib or acalabrutinib (BTK inhibitor); venetoclax + obinutuzumab (BCL-2 + anti-CD20); FCR for fit young patients
Progression after BTK inhibitor or venetoclax therapy
Standard: Switch agent class (BTK→BCL-2 or vice versa), pirtobrutinib (non-covalent BTK inhibitor), CAR-T cell therapy
CLL transforms into aggressive diffuse large B-cell lymphoma
Standard: R-CHOP or similar immunochemotherapy; clinical trial enrolment strongly recommended; allogeneic stem cell transplant in eligible patients
Pirtobrutinib is a non-covalent (reversible) BTK inhibitor active against CLL resistant to ibrutinib and acalabrutinib. Other novel BTK degraders and BTK chimeric compounds are in early-phase UK trials.
Trials testing venetoclax with acalabrutinib as an all-oral, time-limited regimen; venetoclax with novel CD20 bispecific antibodies; and fixed-duration venetoclax strategies to enable treatment-free remission.
CD19-directed CAR-T therapy for multiply relapsed CLL. UK centres (including UCLH and The Christie) are recruiting for trials testing lisocabtagene maraleucel and novel CAR constructs with improved persistence.
CD20xCD3 bispecific T-cell engagers (glofitamab, epcoritamab) are entering CLL trials after success in lymphoma. These off-the-shelf immunotherapies offer an alternative to CAR-T for relapsed disease.
Loading trials from ClinicalTrials.gov...
CLL and SLL are the same disease — the difference is where the abnormal lymphocytes are found. In CLL they are mainly in the blood and bone marrow; in SLL they are mainly in the lymph nodes.
Yes. Many trials specifically enrol patients whose CLL has progressed on BTK inhibitors or BCL-2 therapy. These studies test next-generation agents, combinations, or cellular therapies designed to overcome resistance.
Yes. CAR-T cell therapy targeting CD19 is available for high-risk CLL through several UK trials, particularly for patients who have failed both BTK inhibitor and venetoclax therapy.
Watch and wait remains standard for early, asymptomatic CLL. Trials are starting to test early intervention with targeted therapies in high-risk genetic subgroups (TP53, NOTCH1, unmutated IGHV) to see if early treatment improves outcomes.
Use our search above to find trials matching your condition and location. Review eligibility criteria carefully.
Talk to your GP or haematologist about any trials you are interested in. They can help determine if a trial is appropriate for you.
Reach out to the trial team directly using the contact information on the ClinicalTrials.gov listing.
If you meet the criteria and decide to participate, you will go through informed consent and begin the trial process.